QNCX - Quince Therapeutics, Inc.

1.02
-0.100   -9.804%

Share volume: 573,386
Last Updated: 04-09-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.03%

PREVIOUS CLOSE
CHG
CHG%
$1.12
-0.10
-0.09%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
6%
Profitability 0%
Dept financing 8%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-16.39%
1 Month
-29.17%
3 Months
-43.02%
6 Months
41.67%
1 Year
3.03%
2 Year
-32.89%
Key data
Stock price
$1.02
P/E Ratio 
0.00
DAY RANGE
$0.99 - $1.10
EPS 
-$1.39
52 WEEK RANGE
$0.51 - $2.45
52 WEEK CHANGE
$2.00
MARKET CAP 
82.283 M
YIELD 
N/A
SHARES OUTSTANDING 
43.277 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
-0.63
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$170,240
AVERAGE 30 VOLUME 
$157,263
Company detail
CEO: Dirk Thye
Region: US
Website: quincetx.com
Employees: 60
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor.

Recent news
loading